Can-Fite BioPharma Ltd. (CANF) - Dilution Analysis

20-F filing | 2.6M shares outstanding

POS AM filing: This POS AM filing registers for resale (1) 28,636,500 ordinary shares represented by 95,455 ADSs issuable upon the exercise of placement agent warrants issued in connection with the RD Offering and PIPE Offering, or the January 2023 Offerings, and (2) 6,939,999,600 ordinary shares represented by 23,133,332 ADSs previously registered in a Registration Statement on Form F-1 (File No. 333-288890), consisting of (i) 4,999,999,800 ordinary shares represented by 16,666,666 ADSs issuable upon the exercise of common warrants issued in the July 2025 Offering, (ii) 1,764,999,900 ordinary shares represented by 5,883,333 ADSs issuable upon the exercise of pre-funded warrants issued in the July 2025 Offering, and (iii) 174,999,900 ordinary shares represented by 583,333 ADSs issuable upon the exercise of placement agent warrants issued in connection with the July 2025 Offering.

POS AM filing: This POS AM filing registers for resale (1) 28,636,500 ordinary shares represented by 95,455 ADSs issuable upon the exercise of placement agent warrants issued in connection with the RD Offering and PIPE Offering, or the January 2023 Offerings, and (2) 6,939,999,600 ordinary shares represented by 23,133,332 ADSs previously registered in a Registration Statement on Form F-1 (File No. 333-288890), consisting of (i) 4,999,999,800 ordinary shares represented by 16,666,666 ADSs issuable upon the exercise of common warrants issued in the July 2025 Offering, (ii) 1,764,999,900 ordinary shares represented by 5,883,333 ADSs issuable upon the exercise of pre-funded warrants issued in the July 2025 Offering, and (iii) 174,999,900 ordinary shares represented by 583,333 ADSs issuable upon the exercise of placement agent warrants issued in connection with the July 2025 Offering.

POS AM filing: This POS AM filing relates to the offering of ordinary shares of Can-Fite Biopharma Ltd. represented by ADSs, including those issuable upon the exercise of placement agent warrants and warrants from previous offerings.

POS AM filing: This POS AM filing relates to the offering of ordinary shares of Can-Fite Biopharma Ltd. represented by ADSs, including shares issuable upon the exercise of warrants.

POS AM filing: This POS AM filing registers for resale 6,968,636,100 ordinary shares of Can-Fite Biopharma Ltd., represented by 23,228,787 ADSs, including shares issuable upon exercise of placement agent warrants and warrants from previous offerings.

F-1 filing: This is an F-1 filing for a company offering ADSs and warrants with the intention of using the proceeds for research and development, clinical trials, working capital and general corporate purposes.

20-F filing | 2983.2M shares outstanding

POS AM filing: This is a POS AM filing detailing the offering of ordinary shares represented by ADSs issuable upon the exercise of placement agent warrants in connection with various private placements.

F-3 filing: F-3 filing for shelf offering of ordinary shares represented by ADSs by selling shareholders.

20-F filing | 1278.3M shares outstanding

F-3 filing: F-3 filing for offering of ordinary shares represented by ADSs by selling shareholders.

F-3 filing: Can-Fite BioPharma Ltd. may offer, issue and sell from time to time up to US$100,000,000 of its ordinary shares, including in the form of American Depositary Shares, warrants to purchase ordinary shares, including in the form of ADSs, subscription rights and a combination of such securities, separately or as units, in one or more offerings.

20-F filing | 815.7M shares outstanding

F-1 filing: This is an F-1 filing for Can-Fite Biopharma Ltd. regarding the registration of 955,909,800 ordinary shares represented by 3,186,366 ADSs for resale by selling shareholders, the shares are issuable upon exercise of warrants issued in January 2023.

POS AM filing: This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of up to 173,447,631 ordinary shares, par value NIS 0.25 per share of Can-Fite Biopharma Ltd., represented by 5,781,588 American Depository Shares, or ADSs, consisting of (1) 10,500,000 ordinary shares represented by 350,000 ADSs previously registered in a Registration Statement on Form F-1 (File No. 333-259085), issuable upon the exercise of placement agent warrants issued in connection with the August 2021 Private Placement, (2) 90,810,150 ordinary shares, represented by 3,027,005 ADSs previously registered in a Registration Statement on Form F-1 (File No. 333-239804) consisting of (i) (x) 58,536,600 ordinary shares represented by 1,951,220 ADSs issuable upon the exercise of warrants issued in a private placement in June 2020, or the June 2020 Private Placement, and (y) 2,853,660 ordinary shares represented by 95,122 ADSs issuable upon the exercise of placement agent warrants issued in connection with the June 2020 Private Placement, and (ii) (x) 25,582,500 ordinary shares represented by 852,750 ADSs issuable upon the exercise of warrants issued in a private placement in July 2020, or the July 2020 Private Placement, and (y) 3,837,390 ordinary shares represented by 127,913 ADSs issuable upon the exercise of placement agent warrants issued in connection with the July 2020 Private Placement, (3) 23,838,030 ordinary shares represented by 794,601 ADSs previously registered in a Registration Statement on Form F-1 (File No. 333- 237443), consisting of (i) 22,278,540 ordinary shares represented by 742,618 ADSs issuable upon the exercise of warrants issued in a private placement in January 2020, or the January 2020 Private Placement, and (ii) 1,559,490 ordinary shares represented by 51,983 ADSs issuable upon the exercise of placement agent warrants issued in connection with the January 2020 Private Placement, (4) 47,742,308 ordinary shares represented by 1,591,410 ADSs previously registered in a Registration Statement on Form F-1 (File No. 333-231209), consisting of (i) 45,000,000 ordinary shares represented by 1,500,000 ADSs issuable upon the exercise of warrants issued in a private placement in May 2019, or the May 2019 Private Placement, (ii) 2,250,000 ordinary shares represented by 75,000 ADSs issuable upon the exercise of placement agent warrants issued in connection with the May 2019 Private Placement, and (iii) 492,308 ordinary shares represented by 16,410 ADSs, issuable upon the exercise of placement agent warrants issued in a private placement in April 2019, or the April 2019 Private Placement, (5) 223,809 ordinary shares represented by 7,460 ADSs previously registered in a Registration Statement on Form F-1 (File No. 333-229719), issuable upon the exercise of placement agent warrants issued in a private placement in January 2019, or the January 2019 Private Placement, and (6) 333,334 ordinary shares represented by 11,111 ADSs, previously registered in a Registration Statement on Form F-1 (File No. 333-226696), issuable upon the exercise of placement agent warrants issued in a private placement in March 2018.

POS AM filing: This is a POS AM filing where selling shareholders are offering ordinary shares represented by ADSs, and the company may receive proceeds from the exercise of warrants. The filing also mentions the number of ordinary shares outstanding as of March 22, 2022, and includes details about shares issuable upon the exercise of stock options and warrants.

20-F filing | 815.7M shares outstanding

F-3 filing: This F-3 filing relates to the offering of ordinary shares represented by American Depository Shares (ADSs) upon the exercise of warrants issued in a private placement in December 2021, and placement agent warrants issued in connection with the December 2021 Private Placement. The selling shareholders will receive all net proceeds from the sale of ordinary shares represented by ADSs covered by this prospectus.

F-1 filing: This F-1 filing describes an offering of up to 160,500,000 ordinary shares represented by 5,350,000 ADSs consisting of ordinary shares issuable upon the exercise of warrants issued in a private placement and placement agent warrants issued in connection with the August 2021 Private Placement.

POS AM filing: This POS AM filing relates to the potential sale of ordinary shares represented by ADSs or warrants or placement agent warrants by selling shareholders, subject to certain ownership limitations based on prior financings.

20-F filing | 463.8M shares outstanding

F-3 filing: The filing is for a shelf offering of ordinary shares, including in the form of American Depositary Shares, warrants to purchase ordinary shares, including in the form of ADSs, subscription rights and a combination of such securities, separately or as units, in one or more offerings, up to US$100,000,000.

POS AM filing: This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of up to 171,624,461 ordinary shares, par value NIS 0.25 per share of Can-Fite Biopharma Ltd., represented by 5,720,815 American Depository Shares, or ADSs

F-1 filing: This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of 96,736,980 ordinary shares, par value NIS 0.25 per share of Can-Fite Biopharma Ltd., represented by 3,224,566 American Depository Shares, or ADSs, consisting of (1) (i) 58,536,600 ordinary shares represented by 1,951,220 ADSs issuable upon the exercise of warrants issued in a private placement in June 2020, or the June 2020 Private Placement, and (ii) 8,780,490 ordinary shares represented by 292,683 ADSs issuable upon the exercise of placement agent warrants issued in connection with the June 2020 Private Placement, and (2) (i) 25,582,500 ordinary shares represented by 852,750 ADSs issuable upon the exercise of warrants issued in a private placement in July 2020, or the July 2020 Private Placement, and (ii) 3,837,390 ordinary shares represented by 127,913 ADSs issuable upon the exercise of placement agent warrants issued in connection with the July 2020 Private Placement.

POS AM filing: This is a POS AM filing detailing the offering of ADSs upon the exercise of investor and placement agent warrants.

POS AM filing: This is a POS AM filing related to the offering of ADSs upon the exercise of investor warrants and placement agent warrants.

F-1 filing: This prospectus relates to the resale, by the selling shareholders, of up to an aggregate of 74,887,490 ordinary shares represented by 2,496,249 American Depository Shares.

20-F filing | 120.7M shares outstanding